Eli Lilly's SWOT analysis: stock soars on GLP-1 success, faces competition challenges
Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...
Hosted on MSN11h
Novo Nordisk secures FDA approval for Ozempic in diabetes with CKD
The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks ...
Revere Journal14h
GLP-1 Weight-loss Drugs Should be made Affordable for All Americans
The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...
BioPharma Dive15h
FDA clears use of Ozempic to protect kidney health
The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...
Healio15h
Increase in online searches for obesity drugs correlates with rise in prescriptions
The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...
healthday15h
FDA Approves Ozempic to Protect Kidneys in Patients With Type 2 Diabetes
A popular diabetes drug just got a major new approval -- and it could be a game-changer for millions of Americans a ...
STAT17h
Pharmalittle: We’re reading about a Super Bowl ad for compounded obesity drugs, a PEPFAR waiver, and more
A Super Bowl ad for weight loss medications from telehealth company Hims & Hers is optimized to engage and infuriate ...